Apixaban with the trade name Eliquis is an orally active, reversible, selective factor Xa inhibitor. Specialist indicates this medication for the treatment of venous thromboembolic events that are taken by mouth.
This anticoagulant prevents thrombin generation and thrombus formation; it decreases the conversion of prothrombin to thrombin. After approval in 2012, Pfizer and Bristol-Myers Squibb developed Apixaban in a joint venture. Apixaban is the third novel oral anticoagulant approved in the U.S. for the management of thromboembolic disease.
The recommended Eliquis dosage for most patients is 5 mg taken orally twice daily. Some of the Eliquis Side Effects are easy bruising and unusual bleeding or bleeding that won’t stop, including nosebleeds and bleeding gums. Eliquis is available through the Eliquis coupon.
Eliquis price for oral tablet 5 mg is around $531 for a supply of 60 tablets, depending on the pharmacy you visit.
In 2012: Apixaban received its approval in Europe.
In 2014: The FDA approved Apixaban as a treatment and secondary prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the U.S.
Apixaban, this anticoagulant, is indicated for:
- Reducing the stroke and embolism in patients with non-valvular atrial fibrillation, diabetes mellitus, or symptomatic heart failure
- Treatment of prophylaxis of deep vein thrombosis (DVT) that may lead to pulmonary embolism(PE) in knee or hip replacement surgery patients.
- Reducing the risk of recurring deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial therapy.
Harmful blood clots sometimes can be formed in the blood vessels of the legs, lungs, brain or heart, and cause a blockage in a patient who had surgery or a fast irregular heartbeat. Apixaban blocks ‘factor Xa’, which is involved in the development of blood clots; Through this blocking, it prevents blood from clotting as quickly or as effectively as normal.
This selective inhibitor of FXa does not require antithrombin III for antithrombotic activity. This medication has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. Apixaban decreases thrombin generation and thrombus development by blocking FXa.
If you are looking for a Turkish pharmaceutical Wholesaler for Apixaban inquiries please contact Dano Health Group.
Eliquis was initially approved for the treatment of both venous thromboembolic events and non-valvular atrial fibrillation. The U.S. FDA approved this drug for the treatment of Deep Vein Thrombosis and pulmonary embolism in 2014.
As a result of this approval and increasing Eliquis distributors, Apixaban sales gained momentum and jumped from $146 million in 2013 to $3.3 billion in 2016.
In the first half of 2017, Apixaban exporter announced that its sales reached $2.3 billion; it reflected the growth of 47% over the prior-year period.
This growth is attributed to higher demand given its increased acceptance and market share gains. It has also become a leading anticoagulant in new-to-brand prescriptions among cardiologists in the U.S., gaining strong traction among physicians for atrial fibrillation.
Bristol-Myers Squibb’s cardiovascular segment, which primarily consists of Apixaban, accounts for over 15% of the company’s value. According to the estimation, This drug will perform well over the next few years in the cardiovascular business.
Turkish pharmaceutical wholesalers alongside other suppliers have expected that Apixaban sales reach a peak of $4.5 billion in 2021. But as the drug nears its patent expiry in 2023, the sales are likely to decline.
Bristol-Myers Squibb and Pfizer, the main Eliquis exporters co-developed this drug. This partnership with Pfizer gives it a strong global reach. It was the last new oral anticoagulant to reach the market, but it beats the expectations. This drug is considered safer than warfarin.
It also has outperformed Johnson and Johnson’s Xarelto in terms of total prescriptions in its class. IMS Health Incorporated reported that Xarelto has 46.5% of the NOAC market, compared with a 42.5% share for Eliquis; it represents a decline in share for Xarelto from a peak of about 60% of the market, while it has enjoyed continuous growth in its market share over the last few years.
Bristol-Myers Squibb recently posted its Q1 results. The company’s overall revenues grew 5%, led by Opdivo and Eliquis sales.
The increasing geriatric population, the prevalence of atrial fibrillation in people over 80 years old, and increasing incidences of deep vein thrombosis and pulmonary embolism are major factors driving the growth of the Apixaban market according to the expectations.
Increasing investment in research and development activities in the pharmaceutical sector and the launch of innovative oral anticoagulant drugs are the other factors fueling the market growth.
Stringent regulations by governments and the risk of side-effects and complications associated with the use of oral anticoagulants will hinder the growth of the global Apixaban market according to the expectations.
Key players are using various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain their position in the Apixaban market.
Some of the major players in the clinical trial product wholesaler market are Pfizer, Medichem, Polpharma, Beijing Cooperate Pharmaceutical, Centaur Pharmaceutical, Deafarma, and Dipharma Francis. Also, it should be noted that clinical trial product wholesalers such as Dano Health are providing Apixaban for the companies who are eager to research this drug.
Researchers segmented the global Apixaban market into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America has the dominant position in terms of revenue creating by the high price of the drug in treating venous thromboembolic events.
According to the expectation, the Asia Pacific market will witness significant growth followed by the European market. This growth will be the result of increasing healthcare initiatives by respective governments.
The study published PLOS ONE 2016 has shown that the cost-effectiveness of Apixaban drug versus warfarin in Chinese patients with non-valvular atrial fibrillation in Hong Kong is the factor that is also propelling the growth of the Apixaban market in the particular region.